Skip to main content

Erratum: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer (Nature Medicine (2004) 10 (145-147))

Publication ,  Journal Article
Willett, CG; Boucher, Y; Di Tomaso, E; Duda, DG; Munn, LL; Tong, RT; Chung, DC; Sahani, DV; Kalva, SP; Kozin, SV; Mino, M; Cohen, KS; Zhu, AX ...
Published in: Nature Medicine
January 1, 2004

Duke Scholars

Published In

Nature Medicine

DOI

ISSN

1078-8956

Publication Date

January 1, 2004

Volume

10

Issue

6

Start / End Page

649

Related Subject Headings

  • Immunology
  • 42 Health sciences
  • 32 Biomedical and clinical sciences
  • 11 Medical and Health Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Willett, C. G., Boucher, Y., Di Tomaso, E., Duda, D. G., Munn, L. L., Tong, R. T., … Jain, R. K. (2004). Erratum: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer (Nature Medicine (2004) 10 (145-147)). Nature Medicine, 10(6), 649. https://doi.org/10.1038/nm0604-649c
Willett, C. G., Y. Boucher, E. Di Tomaso, D. G. Duda, L. L. Munn, R. T. Tong, D. C. Chung, et al. “Erratum: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer (Nature Medicine (2004) 10 (145-147)).” Nature Medicine 10, no. 6 (January 1, 2004): 649. https://doi.org/10.1038/nm0604-649c.
Willett CG, Boucher Y, Di Tomaso E, Duda DG, Munn LL, Tong RT, et al. Erratum: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer (Nature Medicine (2004) 10 (145-147)). Nature Medicine. 2004 Jan 1;10(6):649.
Willett, C. G., et al. “Erratum: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer (Nature Medicine (2004) 10 (145-147)).” Nature Medicine, vol. 10, no. 6, Jan. 2004, p. 649. Scopus, doi:10.1038/nm0604-649c.
Willett CG, Boucher Y, Di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain RK. Erratum: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer (Nature Medicine (2004) 10 (145-147)). Nature Medicine. 2004 Jan 1;10(6):649.

Published In

Nature Medicine

DOI

ISSN

1078-8956

Publication Date

January 1, 2004

Volume

10

Issue

6

Start / End Page

649

Related Subject Headings

  • Immunology
  • 42 Health sciences
  • 32 Biomedical and clinical sciences
  • 11 Medical and Health Sciences